PY2089159A - Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting - Google Patents

Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting

Info

Publication number
PY2089159A
PY2089159A PY202002089159A PY2089159A PY2089159A PY 2089159 A PY2089159 A PY 2089159A PY 202002089159 A PY202002089159 A PY 202002089159A PY 2089159 A PY2089159 A PY 2089159A PY 2089159 A PY2089159 A PY 2089159A
Authority
PY
Paraguay
Prior art keywords
sting
compositions
activity
compounds
conditions associated
Prior art date
Application number
PY202002089159A
Other languages
English (en)
Spanish (es)
Inventor
Jason Katz
William R Roush
Hans Martin Seidel
Shankar Venkatraman
Original Assignee
Ifm Due Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ifm Due Inc filed Critical Ifm Due Inc
Publication of PY2089159A publication Critical patent/PY2089159A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PY202002089159A 2019-12-31 2020-12-30 Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting PY2089159A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962955839P 2019-12-31 2019-12-31
US202063090538P 2020-10-12 2020-10-12

Publications (1)

Publication Number Publication Date
PY2089159A true PY2089159A (es) 2022-05-11

Family

ID=74206237

Family Applications (1)

Application Number Title Priority Date Filing Date
PY202002089159A PY2089159A (es) 2019-12-31 2020-12-30 Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting

Country Status (8)

Country Link
US (1) US20230127839A1 (cg-RX-API-DMAC7.html)
EP (1) EP4085051A1 (cg-RX-API-DMAC7.html)
JP (1) JP7756643B2 (cg-RX-API-DMAC7.html)
CN (2) CN115348957B (cg-RX-API-DMAC7.html)
PY (1) PY2089159A (cg-RX-API-DMAC7.html)
TW (1) TW202136239A (cg-RX-API-DMAC7.html)
UY (1) UY39006A (cg-RX-API-DMAC7.html)
WO (1) WO2021138434A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI873098B (zh) 2018-07-03 2025-02-21 瑞士商諾華製藥公司 用於治療與sting活性相關之病症的化合物及組合物
JP2024500877A (ja) 2020-12-22 2024-01-10 アイエフエム デュー インコーポレイテッド がんを処置する方法
JP2024500874A (ja) 2020-12-22 2024-01-10 アイエフエム デュー インコーポレイテッド がんを処置する方法
JP2024504002A (ja) 2020-12-22 2024-01-30 アイエフエム デュー インコーポレイテッド がんを処置する方法
US20240122903A1 (en) 2020-12-22 2024-04-18 Ifm Due Inc. Methods of treating cancer
WO2022150560A1 (en) * 2021-01-08 2022-07-14 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
JP2024502474A (ja) 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物
CN116981668A (zh) * 2021-04-09 2023-10-31 百济神州(北京)生物科技有限公司 制备bcl-2抑制剂的中间体的方法
AU2022326463A1 (en) 2021-08-10 2024-02-22 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN117756698A (zh) * 2022-12-16 2024-03-26 中国药科大学 脲类化合物及其作为sting抑制剂的医药用途
CN116023321B (zh) * 2022-12-30 2024-11-29 中国药科大学 Sting抑制剂前药及其医药用途
CN120794957A (zh) * 2024-05-14 2025-10-17 中国药科大学 苯并含氮杂环类sting抑制剂及其医药用途
CN120794982A (zh) * 2024-05-14 2025-10-17 中国药科大学 吡唑类sting抑制剂及其医药用途
WO2026023667A1 (ja) * 2024-07-25 2026-01-29 カルナバイオサイエンス株式会社 フェニルピペラジン誘導体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5783558A (en) * 1980-11-13 1982-05-25 Asahi Chem Ind Co Ltd Novel organic compound and its preparation
JPS5783557A (en) * 1980-11-14 1982-05-25 Asahi Chem Ind Co Ltd Novel azomethine compound and its preparation
US20120046290A1 (en) * 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
KR20040047869A (ko) 2001-09-26 2004-06-05 파마시아 이탈리아 에스.피.에이. 키나제 억제제로서 활성인 아미노인다졸 유도체, 이의제조방법 및 이를 함유하는 약제학적 조성물
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP2013545740A (ja) 2010-11-10 2013-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング バニロイド受容体リガンドとしての置換された複素芳香族カルボキサミド誘導体および尿素誘導体
WO2012075380A1 (en) 2010-12-03 2012-06-07 The Trustees Of The University Of Pennsylvania Tip60 inhibitors
CN102516153B (zh) 2011-12-14 2014-03-12 南京工业大学 5-氟吲哚-2-酮-3-脲类化合物及其制备方法和应用
AU2014278231B2 (en) 2013-06-11 2017-05-25 KALA BIO, Inc. Urea derivatives and uses thereof
AU2014340269B2 (en) 2013-10-21 2018-06-21 Drexel University Use of STING agonists to treat chronic hepatitis B virus infection
CN107417478B (zh) 2017-06-05 2020-05-05 南京师范大学 一种催化氧化羰基化合成不对称二取代脲的方法
EP3556362A1 (en) 2018-04-16 2019-10-23 Ecole Polytechnique Federale De Lausanne (Epfl) Sting inhibitors
WO2020191227A1 (en) * 2019-03-20 2020-09-24 Cornell University Methods for controlling prostaglandin-mediated biological processes
JP2024500877A (ja) * 2020-12-22 2024-01-10 アイエフエム デュー インコーポレイテッド がんを処置する方法
US20240122903A1 (en) * 2020-12-22 2024-04-18 Ifm Due Inc. Methods of treating cancer
JP2024504002A (ja) * 2020-12-22 2024-01-30 アイエフエム デュー インコーポレイテッド がんを処置する方法
JP2024500874A (ja) * 2020-12-22 2024-01-10 アイエフエム デュー インコーポレイテッド がんを処置する方法

Also Published As

Publication number Publication date
US20230127839A1 (en) 2023-04-27
JP7756643B2 (ja) 2025-10-20
CN120965654A (zh) 2025-11-18
UY39006A (es) 2021-07-30
JP2023509422A (ja) 2023-03-08
EP4085051A1 (en) 2022-11-09
CN115348957A (zh) 2022-11-15
CN115348957B (zh) 2025-11-25
WO2021138434A1 (en) 2021-07-08
TW202136239A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
PY2026348A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
PY2089151A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
PY2060666A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
UY39006A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
PY2157405A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting
PY2201430A (es) Compuestos y composiciones para tratar condiciones asociadas con la actividad de sting
EA201891565A1 (ru) Соединения и композиции для лечения состояний, ассоциированных с активностью sting
MX2018012249A (es) Moduladores de nlpr3.
CO2019008932A2 (es) Imidazo-quinolinas sustituidas como moduladores de nlrp3
WO2022133046A3 (en) Compounds and compositions for treating conditions associated with sting activity
CL2023000856A1 (es) Compuestos derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer
MX2021009178A (es) Composiciones de oligonucleotidos y metodos de las mismas.
PY2301792A (es) Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting
CL2025004052A1 (es) Derivados pirazolo[3,2-c]piridinona, inhibidores egfr y/o her2; composición; uso en cáncer
CO2024002311A2 (es) Compuestos y composiciones para tratar condiciones asociadas con actividad de sting
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
WO2022133098A3 (en) Compounds and compositions for treating conditions associated with sting activity
MX2021001985A (es) Metodos agnosticos de conteo de plaquetas para tratar la mielofibrosis.
CL2024000114A1 (es) Compuestos terapéuticos y procedimientos.
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
WO2022072645A3 (en) Pyrrolopyrolidinone and pyrroloazepinone derivatives for use in treating cancer
AR126753A1 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
AR123760A1 (es) Métodos para tratar el cáncer
AR123576A1 (es) Métodos para tratar el cáncer
AR132891A1 (es) Métodos para tratar el cáncer